search
Back to results

Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone

Primary Purpose

Substance-Related Disorders

Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
midazolam(drug), digoxin (drug)
Bupropion (drug)
Methadone (drug)
Sponsored by
University of Washington
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional basic science trial for Substance-Related Disorders focused on measuring Metabolic Networks and Pathways, Methadone, Polymorphism, genetic, Cytochrome P-450 Enzyme System

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy
  • Within 25% of ideal body weight

Exclusion Criteria:

  • Pregnant
  • A prisoner
  • Enemy, non-combatant
  • Smoker
  • Have a history of liver disease
  • Have a history of heart disease
  • Have a history of drug abuse
  • Currently on prescription medication

Sites / Locations

  • University of Washington General Clinical Research CenterRecruiting

Outcomes

Primary Outcome Measures

Explore if there is a correlation between the areas of the concentration curves of probe substrates for CYP3A4 and/or CYP2B6 and Pgp and the area of the concentration curve of methadone.

Secondary Outcome Measures

LC-MS assays will be developed to analyze the plasma content of the probe substrates, methadone and their metabolites. Specifically, midazolam, 1-OH midazolam, bupropion, t-butyl-hydroxy bupropion, digoxin, methadone, and EDDP (a methadone metabolite).
Isolate and bank the DNA of the subjects for future genotyping of variant alleles that will be identified in this study to be important in methadone pharmacokinetics.

Full Information

First Posted
July 18, 2007
Last Updated
October 11, 2010
Sponsor
University of Washington
search

1. Study Identification

Unique Protocol Identification Number
NCT00504413
Brief Title
Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone
Official Title
Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone in Human Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
October 2010
Overall Recruitment Status
Unknown status
Study Start Date
July 2007 (undefined)
Primary Completion Date
January 2011 (Anticipated)
Study Completion Date
January 2011 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
University of Washington

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine to what extent CYP2B6, CYP3A4, and MDR1 polymorphisms affect the metabolism of methadone.
Detailed Description
Methadone maintenance treatment (MMT) has been used to rehabilitate the opiate addict resulting in a higher quality of life for the patient as well as improving social and psychological functioning while reducing the overall cost to society. The maintenance dose of methadone is highly variable between patients, and drug-drug interactions have been observed between methadone and various medications used to treat a variety of diseases. Identification and understanding of the enzymes responsible for the metabolism of methadone could potentially lead to improved strategy in individualizing methadone dosing and reduce the risk of adverse drug interactions. Several cytochrome P450 enzymes (CYPs) have been identified and hypothesized to be involved in methadone metabolism in vitro, particularly CYP2B6 and CYP3A4. However, the quantitative contribution of CYP2B6 and CYP3A4 in the elimination clearance of methadone in vivo remains undefined. In addition, methadone is a substrate of the efflux transporter, P-glycoprotein (Pgp) at the intestinal mucosa. We are proposing a pilot study in healthy human subjects to investigate the following hypotheses: Pgp limits the gastrointestinal absorption Inter-subject variations in CYP2B6 and CYP3A4 activities explain the variation in methadone clearance in vivo This will be accomplished by correlating the pharmacokinetics of methadone and the phenotype probes for Pgp (digoxin), CYP2B6 (bupropion) and CYP3A4 (midazolam). We plan to use these data to design a human subject study to assess the utility of MDR1 and CYP genotyping in predicting the methadone maintenance dose in a cohort of MMT patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Substance-Related Disorders
Keywords
Metabolic Networks and Pathways, Methadone, Polymorphism, genetic, Cytochrome P-450 Enzyme System

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
midazolam(drug), digoxin (drug)
Intervention Description
Midazolam (2mg po) and digoxin (0.5mg po) will be administered one time, an hour apart. Blood concentration will be collected at various points in an 8 hour period.
Intervention Type
Drug
Intervention Name(s)
Bupropion (drug)
Other Intervention Name(s)
Wellbutrin
Intervention Description
Bupropion (150mg po) will be administered one time on a separate visit. Blood concentrations will be collected at various points in a 72 hour period.
Intervention Type
Drug
Intervention Name(s)
Methadone (drug)
Intervention Description
Methadone (10mg po) will be administered at a separate visit 2 weeks after the bupropion visit. The dose is given once. Blood concentrations will be measured at various points in a 72 hour period. Pupil constriction will be measured and urine will be collected during this period as well.
Primary Outcome Measure Information:
Title
Explore if there is a correlation between the areas of the concentration curves of probe substrates for CYP3A4 and/or CYP2B6 and Pgp and the area of the concentration curve of methadone.
Time Frame
two years
Secondary Outcome Measure Information:
Title
LC-MS assays will be developed to analyze the plasma content of the probe substrates, methadone and their metabolites. Specifically, midazolam, 1-OH midazolam, bupropion, t-butyl-hydroxy bupropion, digoxin, methadone, and EDDP (a methadone metabolite).
Time Frame
two years
Title
Isolate and bank the DNA of the subjects for future genotyping of variant alleles that will be identified in this study to be important in methadone pharmacokinetics.
Time Frame
two years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy Within 25% of ideal body weight Exclusion Criteria: Pregnant A prisoner Enemy, non-combatant Smoker Have a history of liver disease Have a history of heart disease Have a history of drug abuse Currently on prescription medication
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jean C Dinh, PharmD
Phone
206.616.2775
Email
jeandinh@u.washington.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Rheem A Totah, PhD
Phone
206.543.9481
Email
rtotah@u.washington.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rheem A Totah, PhD
Organizational Affiliation
University of Washington, Medicinal Chemistry Department
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Washington General Clinical Research Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98105
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rheem A Totah, PhD
First Name & Middle Initial & Last Name & Degree
Danny Shen, PhD
First Name & Middle Initial & Last Name & Degree
Gregory Terman, MD
First Name & Middle Initial & Last Name & Degree
Kristin K Patton, MD
First Name & Middle Initial & Last Name & Degree
Jean C Dinh, BS

12. IPD Sharing Statement

Citations:
PubMed Identifier
4386743
Citation
Beckett AH, Taylor JF, Casy AF, Hassan MM. The biotransformation of methadone in man: synthesis and identification of a major metabolite. J Pharm Pharmacol. 1968 Oct;20(10):754-62. doi: 10.1111/j.2042-7158.1968.tb09634.x. No abstract available.
Results Reference
background
PubMed Identifier
12220607
Citation
Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat. 2002 Sep;23(2):93-105. doi: 10.1016/s0740-5472(02)00259-3.
Results Reference
background
PubMed Identifier
12804430
Citation
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;(2):CD002209. doi: 10.1002/14651858.CD002209.
Results Reference
background
PubMed Identifier
2031687
Citation
Brettle RP. HIV and harm reduction for injection drug users. AIDS. 1991 Feb;5(2):125-36. doi: 10.1097/00002030-199102000-00001. No abstract available.
Results Reference
background
Citation
Ward J, Mattrick R, Hall W. Methadone maintenance treatment and other opioid replacement therapies. Harwood Academic Publishers, Amsterdam. 1998
Results Reference
background
PubMed Identifier
10065120
Citation
Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust. 1999 Feb 1;170(3):104-9. doi: 10.5694/j.1326-5377.1999.tb127675.x.
Results Reference
background
PubMed Identifier
10706972
Citation
Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000 Apr 1;59(1):17-31. doi: 10.1016/s0376-8716(99)00104-0.
Results Reference
background
PubMed Identifier
12745356
Citation
Stenbacka M, Leifman A, Romelsjo A. The impact of methadone treatment on registered convictions and arrests in HIV-positive and HIV-negative men and women with one or more treatment periods. Drug Alcohol Rev. 2003 Mar;22(1):27-34. doi: 10.1080/0959523021000059802.
Results Reference
background
PubMed Identifier
12810144
Citation
Wong KH, Lee SS, Lim WL, Low HK. Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users. J Subst Abuse Treat. 2003 Apr;24(3):233-9. doi: 10.1016/s0740-5472(03)00029-1.
Results Reference
background
PubMed Identifier
14612485
Citation
Bruera E, Kim HN. Cancer pain. JAMA. 2003 Nov 12;290(18):2476-9. doi: 10.1001/jama.290.18.2476. No abstract available.
Results Reference
background
PubMed Identifier
3528988
Citation
Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain. 1986 Jun;25(3):297-312. doi: 10.1016/0304-3959(86)90234-4.
Results Reference
background
PubMed Identifier
9106815
Citation
Manfredi PL, Borsook D, Chandler SW, Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain. 1997 Mar;70(1):99-101. doi: 10.1016/s0304-3959(96)03313-1.
Results Reference
background
PubMed Identifier
15102407
Citation
Mercadante S. Methadone in cancer pain. Eur J Pain. 1997;1(2):77-83; discussion 84-5. doi: 10.1016/s1090-3801(97)90064-1.
Results Reference
background
PubMed Identifier
12170567
Citation
Ripamonti C, Bianchi M. The use of methadone for cancer pain. Hematol Oncol Clin North Am. 2002 Jun;16(3):543-55. doi: 10.1016/s0889-8588(02)00017-5.
Results Reference
background
PubMed Identifier
7823756
Citation
Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 1995;56(2):PL45-50. doi: 10.1016/0024-3205(94)00426-s.
Results Reference
background
PubMed Identifier
11910269
Citation
Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, Kosel M, Baumann P, Eap CB. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol. 2002 Apr;22(2):211-5. doi: 10.1097/00004714-200204000-00017.
Results Reference
background
PubMed Identifier
5081605
Citation
Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther. 1972 Nov-Dec;13(6):923-30. doi: 10.1002/cpt1972136923. No abstract available.
Results Reference
background
PubMed Identifier
16187972
Citation
Hanna J, Foster DJ, Salter A, Somogyi AA, White JM, Bochner F. Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. Br J Clin Pharmacol. 2005 Oct;60(4):404-13. doi: 10.1111/j.1365-2125.2005.02464.x.
Results Reference
background
PubMed Identifier
15661442
Citation
Peles E, Schreiber S, Gordon J, Adelson M. Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain. 2005 Feb;113(3):340-346. doi: 10.1016/j.pain.2004.11.011.
Results Reference
background
PubMed Identifier
11206036
Citation
Charlier C, Dessalles MC, Plomteux G. Methadone maintenance treatment: is it possible to adapt the daily doses to the metabolic activity of the patient? Ther Drug Monit. 2001 Feb;23(1):1-3. doi: 10.1097/00007691-200102000-00001.
Results Reference
background
PubMed Identifier
12609702
Citation
Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend. 2003 Mar 1;69(2):205-11. doi: 10.1016/s0376-8716(02)00320-4.
Results Reference
background
PubMed Identifier
12405865
Citation
Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93. doi: 10.2165/00003088-200241140-00003.
Results Reference
background
PubMed Identifier
11069437
Citation
Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2000 Nov;50(5):427-40. doi: 10.1046/j.1365-2125.2000.00272.x.
Results Reference
background
PubMed Identifier
9020195
Citation
Iribarne C, Dreano Y, Bardou LG, Menez JF, Berthou F. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology. 1997 Feb 14;117(1):13-23. doi: 10.1016/s0300-483x(96)03549-4.
Results Reference
background
PubMed Identifier
12882588
Citation
Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet. 2003;42(9):819-50. doi: 10.2165/00003088-200342090-00003.
Results Reference
background
PubMed Identifier
14628297
Citation
Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004 Jan;16(1):36-44. doi: 10.1002/chir.10303.
Results Reference
background
PubMed Identifier
15371986
Citation
Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69. doi: 10.1016/j.clpt.2004.05.003.
Results Reference
background
PubMed Identifier
15289792
Citation
Moody DE, Walsh SL, Rollins DE, Neff JA, Huang W. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals. Clin Pharmacol Ther. 2004 Aug;76(2):154-66. doi: 10.1016/j.clpt.2004.04.004.
Results Reference
background
PubMed Identifier
11504799
Citation
Oda Y, Kharasch ED. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther. 2001 Sep;298(3):1021-32.
Results Reference
background
PubMed Identifier
12756206
Citation
Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos. 2003 Jun;31(6):742-7. doi: 10.1124/dmd.31.6.742.
Results Reference
background
PubMed Identifier
11452244
Citation
Boulton DW, Arnaud P, DeVane CL. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther. 2001 Jul;70(1):48-57. doi: 10.1067/mcp.2001.116793.
Results Reference
background
PubMed Identifier
14977870
Citation
Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, Yan B, Negishi M, LeCluyse EL. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58. doi: 10.1124/dmd.32.3.348.
Results Reference
background
PubMed Identifier
14604466
Citation
Hesse LM, Sakai Y, Vishnuvardhan D, Li AP, von Moltke LL, Greenblatt DJ. Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. J Pharm Pharmacol. 2003 Sep;55(9):1229-39. doi: 10.1211/0022357021657.
Results Reference
background
PubMed Identifier
12739762
Citation
Martin H, Sarsat JP, de Waziers I, Housset C, Balladur P, Beaune P, Albaladejo V, Lerche-Langrand C. Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res. 2003 Apr;20(4):557-68. doi: 10.1023/a:1023234429596.
Results Reference
background
PubMed Identifier
15364537
Citation
Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209. doi: 10.1016/j.taap.2004.01.010.
Results Reference
background
PubMed Identifier
12573484
Citation
Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta. 2003 Feb 17;1619(3):243-53. doi: 10.1016/s0304-4165(02)00483-x.
Results Reference
background
PubMed Identifier
16338275
Citation
Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, Monnat M, Huttemann H, Baumann P, Eap CB. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005 Dec;78(6):593-604. doi: 10.1016/j.clpt.2005.08.011.
Results Reference
background
PubMed Identifier
16413243
Citation
Lotsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmoller J, Geisslinger G. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther. 2006 Jan;79(1):72-89. doi: 10.1016/j.clpt.2005.09.010.
Results Reference
background
PubMed Identifier
12814665
Citation
Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology. 2003 Jul;45(1):122-32. doi: 10.1016/s0028-3908(03)00136-9.
Results Reference
background
PubMed Identifier
9890159
Citation
Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. doi: 10.1080/004982598238886. No abstract available.
Results Reference
background
PubMed Identifier
12415123
Citation
de Boer AG, van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol. 2003;43:629-56. doi: 10.1146/annurev.pharmtox.43.100901.140204. Epub 2002 Jan 10.
Results Reference
background
PubMed Identifier
12005113
Citation
Fricker G, Miller DS. Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo. Pharmacol Toxicol. 2002 Jan;90(1):5-13. doi: 10.1034/j.1600-0773.2002.900103.x.
Results Reference
background
PubMed Identifier
10706193
Citation
Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000 Feb;38(2):69-74. doi: 10.5414/cpp38069.
Results Reference
background
PubMed Identifier
16580901
Citation
Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins PB, Schuetz E. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther. 2006 Apr;79(4):325-38. doi: 10.1016/j.clpt.2005.11.013. Epub 2006 Feb 20.
Results Reference
background
PubMed Identifier
12489979
Citation
Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42(1):59-98. doi: 10.2165/00003088-200342010-00003.
Results Reference
background
PubMed Identifier
10456292
Citation
Bouer R, Barthe L, Philibert C, Tournaire C, Woodley J, Houin G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol. 1999;13(4):494-500. doi: 10.1111/j.1472-8206.1999.tb00009.x.
Results Reference
background
PubMed Identifier
8101846
Citation
Callaghan R, Riordan JR. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem. 1993 Jul 25;268(21):16059-64.
Results Reference
background
PubMed Identifier
11408360
Citation
Stormer E, Perloff MD, von Moltke LL, Greenblatt DJ. Methadone inhibits rhodamine123 transport in Caco-2 cells. Drug Metab Dispos. 2001 Jul;29(7):954-6.
Results Reference
background
PubMed Identifier
10781286
Citation
Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 2000 May;92(5):1392-9. doi: 10.1097/00000542-200005000-00030.
Results Reference
background
PubMed Identifier
15089813
Citation
Kharasch ED, Hoffer C, Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol. 2004 May;57(5):600-10. doi: 10.1111/j.1365-2125.2003.02053.x.
Results Reference
background
PubMed Identifier
14712343
Citation
Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berl). 2004 Apr;173(1-2):132-8. doi: 10.1007/s00213-003-1718-1. Epub 2004 Jan 8.
Results Reference
background
PubMed Identifier
10803676
Citation
Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000 Apr;10(3):187-216. doi: 10.1097/00008571-200004000-00001.
Results Reference
background
PubMed Identifier
11061577
Citation
Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS Jr. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther. 2000 Oct;68(4):375-83. doi: 10.1067/mcp.2000.109519.
Results Reference
background
PubMed Identifier
5477259
Citation
Doherty JE, Flanigan WJ, Murphy ML, Bulloch RT, Dalrymple GL, Beard OW, Perkins WH. Tritiated digoxin. XIV. Enterohepatic circulation, absorption, and excretion studies in human volunteers. Circulation. 1970 Nov;42(5):867-73. doi: 10.1161/01.cir.42.5.867. No abstract available.
Results Reference
background
PubMed Identifier
892949
Citation
Klotz U, Antonin KH. Biliary excretion studies with digoxin in man. Int J Clin Pharmacol Biopharm. 1977 Jul;15(7):332-4.
Results Reference
background
PubMed Identifier
14534519
Citation
Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2003 Oct;74(4):326-33. doi: 10.1016/S0009-9236(03)00202-9.
Results Reference
background
PubMed Identifier
15155554
Citation
Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos. 2004 Jun;32(6):626-31. doi: 10.1124/dmd.32.6.626.
Results Reference
background
Citation
Rosner B. Fundamentals of Biostatistics. Duxbury, 2006.
Results Reference
background
PubMed Identifier
15315782
Citation
Whittington D, Sheffels P, Kharasch ED. Stereoselective determination of methadone and the primary metabolite EDDP in human plasma by automated on-line extraction and liquid chromatography mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 5;809(2):313-21. doi: 10.1016/j.jchromb.2004.06.041.
Results Reference
background
PubMed Identifier
15993663
Citation
Jabor VA, Coelho EB, Dos Santos NA, Bonato PS, Lanchote VL. A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Aug 5;822(1-2):27-32. doi: 10.1016/j.jchromb.2005.05.011.
Results Reference
background
PubMed Identifier
9187389
Citation
Tracqui A, Kintz P, Ludes B, Mangin P. High-performance liquid chromatography-ionspray mass spectrometry for the specific determination of digoxin and some related cardiac glycosides in human plasma. J Chromatogr B Biomed Sci Appl. 1997 Apr 25;692(1):101-9. doi: 10.1016/s0378-4347(96)00462-8.
Results Reference
background
PubMed Identifier
9378846
Citation
Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol. 1997 Aug;37(8):737-43. doi: 10.1002/j.1552-4604.1997.tb04361.x.
Results Reference
background
Citation
Allen DM. The prediction sum of squares as a criterion for selecting predictor variables. In University of Ky Dept of Statistics Tech Report 23, 1971
Results Reference
background

Learn more about this trial

Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone

We'll reach out to this number within 24 hrs